LDL apheresis activates the complement system and the cytokine network, whereas PCSK9 inhibition with evolocumab induces no inflammatory response

详细信息    查看全文

• 作者：Knut Tore Lappegå ; rd ; MD ; PhD^a ; ^b ; ^{knut.tore.lappegard@gmail.com} ; Terje Enebakk ; RN^c ; Hilde Thunhaug ; RN^c ; Judith Krey Ludviksen ; BSc^d ; Tom Eirik Mollnes ; MD ; PhD^d ; ^e ; ^f ; ^g ; ^h ; Anders Hovland ; MD ; PhD^a ; ^b
• 关键词：Familial hypercholesterolemia ; LDL apheresis ; PCSK9 inhibition ; Innate immunity ; Complement ; Inflammation ; Evolocumab
• 刊名：Journal of Clinical Lipidology
• 出版年：2016
• 出版时间：November-December 2016
• 年：2016
• 卷：10
• 期：6
• 页码：1481-1487
• 全文大小：748 K
• 卷排序：10

文摘

LDL apheresis is well established as treatment in selected high-risk coronary patients. LDL apheresis induces an inflammatory response, including complement activation. PCSK9 inhibition efficiently lowers LDL levels and may prove to be a good alternative to LDL apheresis. PCSK9 inhibition with evolocumab induces no inflammatory response.